2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice …
FLJ Visseren, F Mach, YM Smulders… - European heart …, 2021 - academic.oup.com
Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …
The changing landscape of atherosclerosis
P Libby - Nature, 2021 - nature.com
Emerging evidence has spurred a considerable evolution of concepts relating to
atherosclerosis, and has called into question many previous notions. Here I review this …
atherosclerosis, and has called into question many previous notions. Here I review this …
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of …
G Mancia, R Kreutz, M Brunström, M Burnier… - Journal of …, 2023 - journals.lww.com
Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …
2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on …
Writing Committee Members, JS Lawton… - Journal of the American …, 2022 - jacc.org
Aim The guideline for coronary artery revascularization replaces the 2011 coronary artery
bypass graft surgery and the 2011 and 2015 percutaneous coronary intervention guidelines …
bypass graft surgery and the 2011 and 2015 percutaneous coronary intervention guidelines …
Long-term evolocumab in patients with established atherosclerotic cardiovascular disease
ML O'Donoghue, RP Giugliano, SD Wiviott, D Atar… - Circulation, 2022 - Am Heart Assoc
Background: In FOURIER (Further Cardiovascular Outcomes Research With PCSK9
Inhibition in Subjects With Elevated Risk), the proprotein convertase subtilisin-kexin type 9 …
Inhibition in Subjects With Elevated Risk), the proprotein convertase subtilisin-kexin type 9 …
Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics
Y Duan, K Gong, S Xu, F Zhang, X Meng… - Signal Transduction and …, 2022 - nature.com
Disturbed cholesterol homeostasis plays critical roles in the development of multiple
diseases, such as cardiovascular diseases (CVD), neurodegenerative diseases and …
diseases, such as cardiovascular diseases (CVD), neurodegenerative diseases and …
[HTML][HTML] Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials
Background Statin therapy is effective for the prevention of atherosclerotic cardiovascular
disease and is widely prescribed, but there are persisting concerns that statin therapy might …
disease and is widely prescribed, but there are persisting concerns that statin therapy might …
[HTML][HTML] Профилактика хронических неинфекционных заболеваний в Российской Федерации. Национальное руководство 2022
ОМ Драпкина, АВ Концевая, АМ Калинина… - Кардиоваскулярная …, 2022 - cyberleninka.ru
Члены Комитета экспертов подтвердили отсутствие финансовой поддержки/конфликта
интересов. В случае сообщения о наличии конфликта интересов, член (ы) Комитета …
интересов. В случае сообщения о наличии конфликта интересов, член (ы) Комитета …
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of …
F Mach, C Baigent, AL Catapano… - European heart …, 2020 - academic.oup.com
version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …
Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation …
Background Circulating lipoprotein lipids cause coronary heart disease (CHD). However,
the precise way in which one or more lipoprotein lipid-related entities account for this …
the precise way in which one or more lipoprotein lipid-related entities account for this …